JP2015511221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511221A5 JP2015511221A5 JP2014553763A JP2014553763A JP2015511221A5 JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5 JP 2014553763 A JP2014553763 A JP 2014553763A JP 2014553763 A JP2014553763 A JP 2014553763A JP 2015511221 A5 JP2015511221 A5 JP 2015511221A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fxii
- pharmaceutical composition
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 108010080865 Factor XII Proteins 0.000 claims 11
- 102000000429 Factor XII Human genes 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102100036774 Afamin Human genes 0.000 claims 1
- 101710149366 Afamin Proteins 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 108010087765 Antipain Proteins 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 102100022977 Antithrombin-III Human genes 0.000 claims 1
- 108700015781 Cucurbita maxima CMTI Proteins 0.000 claims 1
- 240000001980 Cucurbita pepo Species 0.000 claims 1
- 235000009852 Cucurbita pepo Nutrition 0.000 claims 1
- 101710194146 Ecotin Proteins 0.000 claims 1
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 241000287826 Gallus Species 0.000 claims 1
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 claims 1
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 241000269908 Platichthys flesus Species 0.000 claims 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims 1
- 229960004405 aprotinin Drugs 0.000 claims 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000051433 human GC Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592652P | 2012-01-31 | 2012-01-31 | |
| US61/592,652 | 2012-01-31 | ||
| EP12153341.8A EP2623110A1 (en) | 2012-01-31 | 2012-01-31 | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| EP12153341.8 | 2012-01-31 | ||
| PCT/EP2013/051832 WO2013113774A1 (en) | 2012-01-31 | 2013-01-31 | Factor xii inhibitors for the treatment of neurological inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511221A JP2015511221A (ja) | 2015-04-16 |
| JP2015511221A5 true JP2015511221A5 (enExample) | 2016-01-14 |
| JP6243854B2 JP6243854B2 (ja) | 2017-12-06 |
Family
ID=45554534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553763A Active JP6243854B2 (ja) | 2012-01-31 | 2013-01-31 | 神経炎症性障害の処置のための第xii因子阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9957329B2 (enExample) |
| EP (2) | EP2623110A1 (enExample) |
| JP (1) | JP6243854B2 (enExample) |
| KR (1) | KR102067394B1 (enExample) |
| CN (1) | CN104080470B (enExample) |
| AU (1) | AU2013200498B2 (enExample) |
| CA (1) | CA2862903C (enExample) |
| DK (1) | DK2809336T3 (enExample) |
| ES (1) | ES2687018T3 (enExample) |
| PL (1) | PL2809336T3 (enExample) |
| WO (1) | WO2013113774A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6109081B2 (ja) | 2011-03-09 | 2017-04-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 人工表面との接触を含む医学的手技に伴う投与のためのfxii阻害剤 |
| US10286047B2 (en) | 2013-03-08 | 2019-05-14 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| EP3068424B1 (en) | 2013-11-13 | 2020-09-09 | Shire ViroPharma LLC | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders |
| DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| KR101744959B1 (ko) | 2014-12-05 | 2017-06-12 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| EP3240570B1 (en) | 2015-01-02 | 2025-09-24 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| JPWO2016114386A1 (ja) * | 2015-01-15 | 2017-10-19 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患治療剤 |
| EA201890340A1 (ru) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | Моноклональное антитело-ингибитор фактора xiia |
| AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
| KR20230136687A (ko) * | 2016-04-06 | 2023-09-26 | 시에스엘 리미티드 | 죽상동맥경화증의 치료 방법 |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| CA3062123A1 (en) * | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with adipose-derived stem cells |
| CN110709091A (zh) | 2017-05-15 | 2020-01-17 | 干细胞医药有限公司 | 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症 |
| BR112020011240A2 (pt) * | 2017-12-15 | 2020-11-24 | Csl Limited | uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica |
| EA202190056A1 (ru) | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| WO2021253662A1 (zh) * | 2020-06-16 | 2021-12-23 | 宁波康善生物科技有限公司 | 抗fxii纳米抗体或其抗原结合片段及其应用 |
| WO2025019789A1 (en) | 2023-07-19 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| CN120192392B (zh) * | 2025-05-23 | 2025-09-05 | 昆明医科大学 | 一种版纳绳蚋抗栓肽Sibakazin及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| GB9800817D0 (en) * | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| BR0317404A (pt) | 2002-12-20 | 2005-11-16 | Axis Shield Diagnostics Ltd | Variantes do fator xiia |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| JP2007503838A (ja) | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス, インコーポレイティド | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005318464B2 (en) * | 2004-12-23 | 2012-02-23 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| EP3028716B1 (en) * | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
| JP2010518039A (ja) * | 2007-02-12 | 2010-05-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用 |
| CN102369021B (zh) | 2008-12-19 | 2016-09-07 | 宏观基因有限公司 | 共价双抗体及其用途 |
| AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| RS66465B1 (sr) * | 2011-07-22 | 2025-02-28 | Csl Behring Gmbh | Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe |
-
2012
- 2012-01-31 EP EP12153341.8A patent/EP2623110A1/en not_active Ceased
-
2013
- 2013-01-31 PL PL13701651T patent/PL2809336T3/pl unknown
- 2013-01-31 WO PCT/EP2013/051832 patent/WO2013113774A1/en not_active Ceased
- 2013-01-31 JP JP2014553763A patent/JP6243854B2/ja active Active
- 2013-01-31 DK DK13701651.5T patent/DK2809336T3/en active
- 2013-01-31 CA CA2862903A patent/CA2862903C/en active Active
- 2013-01-31 CN CN201380007416.XA patent/CN104080470B/zh active Active
- 2013-01-31 KR KR1020147024214A patent/KR102067394B1/ko active Active
- 2013-01-31 EP EP13701651.5A patent/EP2809336B1/en active Active
- 2013-01-31 US US14/374,300 patent/US9957329B2/en active Active
- 2013-01-31 AU AU2013200498A patent/AU2013200498B2/en active Active
- 2013-01-31 ES ES13701651.5T patent/ES2687018T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511221A5 (enExample) | ||
| JP6656926B2 (ja) | pKal関連疾病の評価、アッセイおよび治療 | |
| CA2901225C (en) | Treatment and prevention of remote ischemia-reperfusion injury | |
| TWI585103B (zh) | 抗baff抗il-17雙特異性抗體 | |
| AU2014301041B2 (en) | Combination therapy using a Factor XII inhibitor and a C1-Inhibitor | |
| JP2022023049A (ja) | バイオ医薬組成物 | |
| JP2013517783A5 (enExample) | ||
| JP2016511823A (ja) | ブラジキニン媒介障害の評価および治療 | |
| US7354585B2 (en) | Methods of treating coagulapathic or thrombotic disorders | |
| JP2019506839A5 (enExample) | ||
| JP2019038834A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| JP2013542914A5 (enExample) | ||
| CA2795168A1 (en) | Factor xii inhibitors for treating interstitial lung disease | |
| KR20160089368A (ko) | 자가면역 질환의 진단 및 치료 | |
| WO2018039514A1 (en) | Antibody-mediated neutralization of ebolaviruses | |
| JP2017524675A5 (enExample) | ||
| CN106029884B (zh) | 新型抗人pai-1抗体 | |
| JP2013539354A5 (enExample) | ||
| KR20230030644A (ko) | 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드 | |
| CA3184718A1 (en) | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| US20240301073A1 (en) | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | |
| JP2019055949A5 (enExample) | ||
| JP7685957B2 (ja) | プロテアーゼネキシン-1に対する立体構造的な単一ドメイン抗体及びその使用 | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| US20230174666A1 (en) | Anti-cd26 proteins and uses thereof |